UFP Technologies reports record 2024 revenue of $504.4M, adj. EPS $8.68, up 31%

UFP TECHNOLOGIES INC

2024-FY EPS reported $7.58 revenue$504,421,000

Full-year net income $59.0M (+31.3%); adjusted net income $67.6M (+32.5%); GAAP EPS $7.58, adj. EPS $8.68.
Q4 sales $144.1M (+41.9%); Q4 adj. net income $19.2M (+51.6%); Q4 adj. EPS $2.46.
MedTech sales grew 48.6% in Q4 and 30.2% for full year; gross margin improved to 29.1% from 28.1%.
Adjusted EBITDA for 2024 reached $107.3M, up 39.1% from $77.2M in 2023.
CEO cites acquisitions performing ahead, Dominican Republic expansion, and two major programs launching H2 2025.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001171843-25-001061
form_type: 8-K
ticker: UFPT
cik: 0000914156
company_name: UFP TECHNOLOGIES INC
filed_at: 2025-02-25T23:59:59+00:00
discovered_at: 2026-05-14T18:03:06.784556+00:00
generated_at: 2026-05-26T05:20:12.448666+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001171843-25-001061
json_url: https://secwatch.observer/filing/0001171843-25-001061.json
markdown_url: https://secwatch.observer/filing/0001171843-25-001061.md
text_url: https://secwatch.observer/filing/0001171843-25-001061.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/914156/000117184325001061/0001171843-25-001061-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/914156/000117184325001061/f8k_022525.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001171843-25-001061

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.